In some patients, the chronic inflammatory skin diseases psoriasis and eczema are so similar that dermatologists have had to examine tissue samples but a team of researchers at the Helmholtz Zentrum München and the Technical University of Munich (TUM) have now analyzed the molecular processes that occur in both diseases and discovered crucial differences.
This has enabled them to develop a diagnostic procedure which in practice enables psoriasis and eczema to be reliably differentiated from one another on the basis of only two genes.
Psoriasis is a non-contagious, inflammatory skin disease and can also be a systemic disease that affects other organs. It generally presents as very flaky patches of skin varying in size from spots to larger areas the size of one’s palms (frequently on the knees, the elbows and on the scalp, and also on the anus) – often with severe itching as well as nail changes. Worldwide about 125 million people suffer from it. Eczema is a skin disease that presents as a non-infectious inflammatory skin reaction and can be triggered by different factors. It is characterized by a typical sequence of skin reactions, such as reddening of the skin, blistering, weeping, scabbing, scaling.
“Both diseases have a highly complex appearance, which often varies widely from one patient to another,” says Dr. Stefanie Eyerich, who heads the Specific Immunology working group at the Institute of Allergy Research (IAF) at the Helmholtz Zentrum München. “This has led previous attempts to compare their molecular signature to fail.” In this study, the researchers identified 24 patients who were suffering simultaneously from psoriasis and eczema and in each analyzed at the molecular level the characteristic differences they demonstrated between psoriasis and eczema compared to clinically unremarkable skin.
“We were thus able to drastically reduce random genetic or environmental influences and gain a detailed picture of the development of these two diseases,” explains Prof. Fabian Theis of the Institute of Computational Biology (ICB) at the Helmholtz Zentrum München.
Paving the way for personalized medicine
In recent years, many new specific treatments have been developed for psoriasis and eczema. However, in each case, these are only effective for one or other of the two diseases. And they are very expensive: one such treatment generally costs several tens of thousands of euros per year, per patient. The ability to make an exact diagnosis therefore has a considerable economic impact.
If it cannot be clearly determined on presentation which of the two diseases is involved, the newly developed diagnostic tool will help to differentiate them. It involves a test which compares samples of diseased and healthy skin and is concluded within one day. The researchers have now filed a patent application for it.
The procedure, moreover, marks the first step towards the introduction of personalized medicine also for chronic inflammatory skin diseases. “Whereas this is practiced increasingly in oncology, for example in the form of mutation analyses and the subsequent decision in favor of the best individual treatment option, it is not common in the case of inflammatory skin diseases,” says Kilian Eyerich of the Clinic and Polyclinic for Dermatology at the Technical University of Munich.
The researchers plan to purse this path with a view to characterizing even more precisely the molecular processes involved in inflammatory skin diseases and combining them with clinical information, such as the choice of certain treatments. In this way, their goal is to determine the best possible treatment option for each individual patient.
Quaranta, M. et al, (2014), Intra-individual genome expression analysis reveals a specific molecular signature of psoriasis and eczema, Sci Transl Med, 2014 July 9th; Vol. 6, Issue 244, p. 244ra90; Sci. Transl. Med. DOI: 10.1126. Source: Helmholtz Zentrum Muenchen
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Prenatal BPA Exposures (Don’t) Affect Birth Weight
- What Do EU Countries Give Up When They Opt-out Of GMO Crops? And For Whom?
- An Easy Problem
- Nobel Prize Validates Chinese Medicine? Nope.
- Another Mainstream Science Publication Calls Out USRTK And Its Media Enablers
- Mother Jones Hates Scientists - And Their Bias Shows
- Difficulty Processing Speech May Be An Effect Of Dyslexia, Not A Cause
- "This is a bit of irony: Mother Jones, which can never be bothered with facts or truth and got sued..."
- "Great piece Steve. While the potential for suffering and death in Africa especially thanks to this..."
- "I look forward to more threats and libel from you in the very near future. It's your stock in trade..."
- "Dear Mr. Campbell: Again you spin and dissemble. It was quite clear from the many tweets between..."
- "One of us does not know what libel means (hint: It is you). Calling me a felon and a fraud is libel..."
- FDA-Approved Test for Meningitis is a Home Run
- Trends In Smoking – Chinese Men In Peril, American Women Get Better Cessation
- Counter-Point: Activists Operate By Outrage, Not Fear
- Whole Foods Recalls Organic Roquefort Cheeses After Listeria Found
- Suicide Tries Linked to Weight-Loss Surgery? Study Doesn’t Show
- Following Rules, Refreezing Thawed Meat is Safe
- Beetles provide clues about the genetic foundations of parenthood
- Trees to power: McMaster engineers build better energy storage device
- High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
- 'Blind analysis' could reduce bias in social sciences papers
- Adoption of streamlined breast cancer treatment has stagnated, study finds